Subtypes of Triple-negative Breast Cancer Cell Lines React Differently to Eribulin Mesylate.

Autor:	Bräutigam K; Department of Gynecology and Obstetrics, University Medical Center Schleswig-Holstein, Lübeck, Germany Karen.Braeutigam@uksh.de., Mitzlaff K; Department of Gynecology and Obstetrics, University Medical Center Schleswig-Holstein, Lübeck, Germany., Uebel L; Department of Gynecology and Obstetrics, University Medical Center Schleswig-Holstein, Lübeck, Germany., Köster F; Department of Gynecology and Obstetrics, University Medical Center Schleswig-Holstein, Lübeck, Germany., Polack S; Department of Gynecology and Obstetrics, University Medical Center Schleswig-Holstein, Lübeck, Germany., Pervan M; Department of Gynecology and Obstetrics, University Medical Center Schleswig-Holstein, Lübeck, Germany., Steinert G; Eisai GmbH, Frankfurt am Main, Germany., Rody A; Department of Gynecology and Obstetrics, University Medical Center Schleswig-Holstein, Lübeck, Germany., Liedtke C; Department of Gynecology and Obstetrics, University Medical Center Schleswig-Holstein, Lübeck, Germany.
Jazyk:	angličtina
Zdroj:	Anticancer research [Anticancer Res] 2016 Jun; Vol. 36 (6), pp. 2759-66.
Abstrakt:	Background/aim: Diagnosis of triple-negative breast cancer (TNBC) is associated with adverse prognosis, particularly in cases of chemotherapy resistance. The goal of this analysis was to compare TNBC vs. non-TNBC cell lines and those of distinct TNBC subtypes with regard to sensitivity to eribulin in vitro. Materials and Methods: Breast cancer cell lines were subjected to cell-viability assays, apoptosis analyses, migration and invasion experiments, and quantitative real-time polymerase chain reaction after exposure to eribulin. Results: Eribulin reduced cell viability in TNBC and non-TNBC cell lines in the sub-nanomolar range. Furthermore, exposure to eribulin induced apoptosis and decreased the rate of migration and invasion. Genes known to induce malignant transformation were differentially expressed after eribulin treatment. Conclusion: Eribulin had a strong antiproliferative effect on breast cancer cell lines, although we did not observe a significant difference between TNBC and non-TNBC cell lines with regard to sensitivity to eribulin. (Copyright© 2016 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu